Literature DB >> 18353371

Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.

Carles Gaig1, Mario Ezquerra, Maria José Martí, Francesc Valldeoriola, Esteban Muñoz, Albert Lladó, Maria Jesús Rey, Adriana Cardozo, José Luis Molinuevo, Eduardo Tolosa.   

Abstract

BACKGROUND: The neuropathology associated with LRRK2 mutations is heterogeneous but Lewy body (LB) type pathology is the most common substrate encountered. While the prevalence of LRRK2 mutations has been extensively studied in Parkinson's disease (PD), limited information is available on the frequency of LRRK2 mutations in dementia with Lewy bodies (DLB) and in other pathological conditions associated with these mutations, such as non-specific nigral degeneration without LB, tau-immunopositive neurofibrillary tangle pathology, and ubiquitin-positive neuronal inclusions resembling those observed in a subtype of frontotemporal lobar degeneration (FTLD-U).
OBJECTIVE: To further investigate the neuropathology associated with LRRK2 mutations.
METHODS: We have screened for the LRRK2 G2019S and codon-1441 (R1441G/C/H) mutations in 110 cases from a Spanish Brain Bank, which include: 66 synucleinopathies (33 PD, 25 DLB and 8 multiple system atrophy cases), 29 tauopathies (21 progressive supranuclear palsy, 3 corticobasal degeneration and 5 tau-positive FTLD cases), 3 cases of non-specific nigral degeneration and 12 tau-negative FTLD (9 FTLD-U and 3 dementia lacking distinctive histology cases).
RESULTS: The G2019S mutation was found in two cases: One case had a clinical and pathological diagnosis of PD and the other suffered from typical PD and on neuropathological examination had non-specific nigral degeneration without LB. A synonymous variant (R1441R; c.4323C>T) was detected in another PD case.
CONCLUSIONS: In this brain bank-based series, LRRK2 G2019S mutation occurred in patients with parkinsonism associated with either typical brainstem LB pathology or non-specific nigral degeneration. LRRK2 mutations were not encountered in other neurodegenerative disorders associated with synuclein and tau deposition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353371     DOI: 10.1016/j.jns.2008.02.010

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 2.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

3.  Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.

Authors:  Monica Sanchez-Contreras; Michael G Heckman; Pawel Tacik; Nancy Diehl; Patricia H Brown; Alexandra I Soto-Ortolaza; Elizabeth A Christopher; Ronald L Walton; Owen A Ross; Lawrence I Golbe; Neill Graff-Radford; Zbigniew K Wszolek; Dennis W Dickson; Rosa Rademakers
Journal:  Mov Disord       Date:  2016-10-06       Impact factor: 10.338

4.  Clinical and pathological characteristics of LRRK2 G2019S patients with PD.

Authors:  Markos Poulopoulos; Etty Cortes; Jean-Paul G Vonsattel; Stanley Fahn; Cheryl Waters; Lucien J Cote; Carol Moskowitz; Lawrence S Honig; Lorraine N Clark; Karen S Marder; Roy N Alcalay
Journal:  J Mol Neurosci       Date:  2011-12-23       Impact factor: 3.444

Review 5.  The neuropathology of genetic Parkinson's disease.

Authors:  Markos Poulopoulos; Oren A Levy; Roy N Alcalay
Journal:  Mov Disord       Date:  2012-03-26       Impact factor: 10.338

6.  Genetic analysis of neurodegenerative diseases in a pathology cohort.

Authors:  Cornelis Blauwendraat; Olga Pletnikova; Joshua T Geiger; Natalie A Murphy; Yevgeniya Abramzon; Gay Rudow; Adamantios Mamais; Marya S Sabir; Barbara Crain; Sarah Ahmed; Liana S Rosenthal; Catherine C Bakker; Faraz Faghri; Ruth Chia; Jinhui Ding; Ted M Dawson; Alexander Pantelyat; Marilyn S Albert; Mike A Nalls; Susan M Resnick; Luigi Ferrucci; Mark R Cookson; Argye E Hillis; Juan C Troncoso; Sonja W Scholz
Journal:  Neurobiol Aging       Date:  2018-11-17       Impact factor: 4.673

7.  Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation.

Authors:  Christian Wider; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Neurodegener Dis       Date:  2010-03-03       Impact factor: 2.977

8.  LRRK2 variation and dementia with Lewy bodies.

Authors:  Michael G Heckman; Alexandra I Soto-Ortolaza; Monica Y Sanchez Contreras; Melissa E Murray; Otto Pedraza; Nancy N Diehl; Ronald Walton; Catherine Labbé; Oswaldo Lorenzo-Betancor; Ryan J Uitti; Jay van Gerpen; Nilüfer Ertekin-Taner; Glenn E Smith; Kejal Kantarci; Rodolfo Savica; David T Jones; Jonathan Graff-Radford; David S Knopman; Val J Lowe; Clifford R Jack; Ronald C Petersen; Joseph E Parisi; Rosa Rademakers; Zbigniew K Wszolek; Neill R Graff-Radford; Tanis J Ferman; Dennis W Dickson; Bradley F Boeve; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2016-07-29       Impact factor: 4.891

Review 9.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 10.  Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

Authors:  Saskia Biskup; Andrew B West
Journal:  Biochim Biophys Acta       Date:  2008-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.